<div id="readability-page-1"><p>10x Genomics (NASDAQ:TXG - Get Free Report)'s share price fell 6.7% during trading on Thursday . The stock traded as low as $16.40 and last traded at $16.3510. 462,460 shares traded hands during trading, a decline of 85% from the average session volume of 3,185,433 shares. The stock had previously closed at $17.53.</p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>A number of research analysts have recently weighed in on TXG shares. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of 10x Genomics in a research note on Monday. Barclays increased their target price on 10x Genomics from $15.00 to $17.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 7th. Wall Street Zen lowered 10x Genomics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. Citigroup  reiterated a &#34;neutral&#34; rating on shares of 10x Genomics in a research report on Thursday. Finally, UBS Group boosted their price objective on shares of 10x Genomics from $13.00 to $14.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and two have issued  a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $15.12.</p><p><b>Check Out Our Latest Report on TXG</b></p><h2>10x Genomics Stock Performance</h2><p>The company has a 50-day moving average of $14.93 and a 200-day moving average of $13.19. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -26.76 and a beta of 2.15. </p><p>10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million during the quarter, compared to analysts' expectations of $142.50 million. During the same quarter in the prior year, the company earned ($0.30) earnings per share. The business's quarterly revenue was down 1.7% compared to the same quarter last year.  As a group, analysts anticipate that  10x Genomics will post -1.43 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In related news, CFO Adam Taich sold 11,888 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the completion of the transaction, the chief financial officer directly owned 297,385 shares in the company, valued at approximately $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the sale, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,432 shares of company stock worth $635,208. Corporate insiders own  9.39% of the company's stock. </p><h2>Institutional Trading of 10x Genomics</h2><p>A number of large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in  10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the period.  Millennium Management LLC lifted its position in  10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after acquiring an additional 4,371,327 shares during the last quarter.  AQR Capital Management LLC lifted its position in  10x Genomics by 241.3% during the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock worth $47,916,000 after acquiring an additional 2,925,372 shares during the last quarter.  Wellington Management Group LLP boosted its holdings in shares of  10x Genomics by 126.6% during the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company's stock worth $50,099,000 after acquiring an additional 2,394,355 shares during the period.  Finally, Quantinno Capital Management LP grew its position in shares of  10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock valued at $25,864,000 after purchasing an additional 1,506,530 shares during the last quarter. Institutional investors and hedge funds own  84.68% of the company's stock. </p><h2>10x Genomics Company Profile</h2> (Get Free Report)<p>10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than 10x Genomics</li><li>Quiet Period Expirations Explained</li><li>The Quantum Fleet: Investing in the New Quantum Standard</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>AI &amp; Quantum's Next Big Winners: 3 Small-Cap Stocks to Watch in 2026</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2><p>Before you consider 10x Genomics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>10x Genomics (NASDAQ:TXG) shares fell 6.7% to $16.3510 with a trading volume of 462,460, down 85% from the average. Analysts have mixed ratings: Weiss Ratings - sell, Barclays - overweight, Wall Street Zen - hold, Citigroup and UBS - neutral. The company reported better-than-expected Q3 earnings but had a negative net margin and return on equity. Insiders sold shares recently. Institutional investors have increased their stakes significantly.</p>

10x Genomics (NASDAQ:TXG) Trading Down 6.7% - Time to Sell?